PDCD1 and non-small cell lung carcinoma: Indeed, a better prognosis in non-small cell lung cancer patients utilizing anti-PD-1 therapy (via pembrolizumab or nivolumab) correlated with lower levels of gMDSCs (and monocytic MDSCs and CD39+ CD8+ T cells) [96].